|Bid||112.32 x 900|
|Ask||113.20 x 800|
|Day's Range||111.33 - 113.82|
|52 Week Range||101.36 - 132.13|
|Beta (3Y Monthly)||0.16|
|PE Ratio (TTM)||13.71|
|Earnings Date||Jan 30, 2020|
|Forward Dividend & Yield||2.58 (2.32%)|
|1y Target Est||124.08|
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes. Empagliflozin 2.5 mg is an SGLT2 inhibitor being developed by Boehringer Ingelheim and Eli Lilly and Company (LLY). A separate brand name has been proposed for empagliflozin 2.5 mg in type 1 diabetes.
Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes. The drug, empagliflozin, was approved in 2014 in doses of 10 mg and 20 mg to help lower blood sugar levels in patients with type 2 diabetes and is marketed as Jardiance.
The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD symptoms.
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once they have been stabilized.
The results are being presented as a late-breaking oral presentation at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting in Atlanta. Taltz was superior to Humira at Week 24 as measured by the primary endpoint of simultaneous achievement of a reduction by at least 50 percent in disease activity as defined by the American College of Rheumatology (ACR50) and complete skin clearance as measured by the Psoriasis Area and Severity Index (PASI 100).
Based on these positive results, Lilly has submitted for U.S. regulatory approval for adults with active non-radiographic axial spondyloarthritis INDIANAPOLIS , Nov. 12, 2019 /PRNewswire/ -- Eli Lilly ...
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Let's check out the charts and technical indicators to see if these two investment approaches are pointing in the same direction. In the daily bar chart of LLY, below, we can see that prices have moved sideways since the beginning of July with buyers coming in around $105 while rallies above $115 plus have failed so far. Trading volume has been featureless since April but the daily On-Balance-Volume (OBV) line has been flat/steady since April.
Thirty-one abstracts supporting Taltz® and Olumiant® highlight the latest innovative data in axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus and rheumatoid arthritis INDIANAPOLIS ...
INDIANAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal ...
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
INDIANAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities. ...
Pharmaceutical stocks rose a single-digit percentage in the first 10 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
INDIANAPOLIS , Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American ...
Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
INDIANAPOLIS , Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28 th Annual Healthcare Conference on Wednesday, November 13, 2019 . Anne White , president ...